CN116211927A

CN116211927A - Hypolipidemic composition containing natural lovastatin and application thereof

Info

Publication number: CN116211927A
Application number: CN202310393371.XA
Authority: CN
Inventors: 张铭
Original assignee: Zisen Technology Co ltd
Current assignee: Zisen Technology Co ltd
Priority date: 2023-04-13
Filing date: 2023-04-13
Publication date: 2023-06-06

Abstract

The invention discloses a blood lipid reducing composition containing natural lovastatin and application thereof, belonging to the technical field of food and medicines, and comprising the following raw materials in parts by weight: 10 parts of monascus lovastatin extract; 40 parts of fructus aurantii extract; 60 parts of krill oil, and the invention adopts ethanol to extract natural monascus lovastatin in the functional red rice, and has simple preparation process, low cost and stable performance; the invention adopts an ultrasonic-assisted double-aqueous-phase system to extract flavonoid active ingredients in the qu bitter orange, and has high extraction efficiency and less impurities; the krill oil is extracted by adopting a biological enzymolysis mode, active ingredients in the krill oil can be reserved, and finally the obtained product has high nutritive value and no organic solvent residue. The invention shows that the composition has remarkable effects of reducing triglyceride and cholesterol in zebra fish, has no larger difference compared with lovastatin which is a positive medicament, and plays a positive role in relieving obesity, reducing blood fat and protecting liver.

Description

Hypolipidemic composition containing natural lovastatin and application thereof

Technical Field

The invention belongs to the technical field of food medicines, and particularly relates to a blood lipid reducing composition containing natural lovastatin and application thereof.

Background

Hyperlipidemia is caused by abnormal blood lipid metabolism in human body, and is manifested by rise of cholesterol (TC) and/or Triglyceride (TG) in blood plasma, and cardiovascular and cerebrovascular diseases such as atherosclerosis, coronary heart disease and myocardial infarction caused by hyperlipidemia have posed serious threat to human health. Meanwhile, because of the influence of a plurality of factors such as the change of living habits and eating habits of people in the new century, the incidence rate of hyperlipidemia has a remarkable increasing trend, and therefore, the blood lipid reduction research has become significant hot content in the research fields of a plurality of subjects such as life science, medicine and food science.

The medical treatment of hyperlipidemia is the main treatment means in clinic at present, the curative effect is definite, the applicability is wide, however, the biggest problem in the clinical treatment of blood lipid reduction at present is the side effect caused by long-term intake of chemical medicines for reducing blood lipid, in particular to the damage to liver and kidney functions of human bodies. Therefore, natural, safe and efficient components are selected from food-derived plants to perform dietary supplementation and intervention as basic treatments for metabolic diseases, and play a very important role in the treatment of hyperlipidemia.

In recent years, more and more researches are focused on digging natural substances with blood lipid reducing activity from plants, and most of plant-based blood lipid reducing products in the market are teabags or plant-based extracts, such as hawthorns, corn silk teabags, kudzuvine root extracts or combined extracts, and the like, but the products have the defects of single active ingredients or undefined target ingredients, different quality control, incomplete blood lipid reducing effects and the like. The lipid regulation is a complex system, relates to multi-path and multi-gene regulation, has feedback association among different lipid-lowering paths, and cannot solve the problem by a single path, so that the synergistic effect of various lipid-lowering functional factors and the influence on the expression of lipid metabolism related genes are researched, a lipid-lowering composition which has stable quality and safe components, can reduce the absorption of exogenous lipid in a body and the synthesis of endogenous lipid and can regulate lipid metabolism in the multi-path, and can solve the problem of hyperlipidemia in an omnibearing way is a main problem to be developed and solved at present.

Disclosure of Invention

The invention aims to reduce the absorption of exogenous lipid, reduce the synthesis of endogenous lipid and regulate lipid metabolism into a pharmacological mechanism of a composition, screen effective components from thousands of natural products and plant-based raw materials, take red yeast containing natural lovastatin, bitter orange with flavonoid medicinal ingredients and krill oil containing rich phospholipids and unsaturated fatty acids as main ingredients of the blood lipid-lowering composition, extract and purify the active ingredients with the blood lipid-lowering efficacy in the components so as to achieve the effects of high extraction efficiency and comprehensive extraction of the effective ingredients, thereby preparing the quality-controllable blood lipid-lowering composition, regulating blood lipid in multiple ways, and being safe and healthy and free of physical burden compared with chemical medicines.

The aim of the invention can be achieved by the following technical scheme:

in a first aspect, the invention provides a blood lipid reducing composition containing natural lovastatin, which comprises the following raw materials in parts by weight:

10 parts of monascus lovastatin extract;

40 parts of fructus aurantii extract;

60 parts of krill oil.

Further, the preparation process of the monascus lovastatin extract comprises the following steps:

a1, crushing functional red rice, sieving with a 40-mesh sieve to obtain functional red rice flour, stirring and extracting the functional red rice flour with 75% ethanol at the extraction temperature of 30-35 ℃ for 2 hours to obtain an extract, centrifuging at 4000rpm/min to separate the extract, collecting supernatant, and repeating the extraction step twice;

a2, combining the two extracts, performing reduced pressure distillation at 35-40 ℃ and 0.06-0.08mpa vacuum degree, recovering ethanol solution, concentrating the ethanol solution, filtering at 20 ℃ and normal pressure to obtain red yeast extract, and performing vacuum reduced pressure drying at 60 ℃ to obtain extract;

and A3, placing the extract in an emulsifying kettle, adding enzymatic soybean phospholipid, heating to 60 ℃, and emulsifying and stirring for 30min under the condition of 120r/min to obtain the oil-soluble monascus lovastatin extract.

Further, the mass ratio of the functional red rice flour to the ethanol in the step A1 is 7:1.

further, the amount of the enzymatic soybean phospholipids in the step A3 is 30% of the mass of the extract.

Further, the preparation process of the qu bitter orange extract comprises the following steps:

b1, crushing the bitter orange, sieving with a 40-mesh sieve, performing ultrasonic-assisted extraction on the bitter orange powder by using a double-water-phase solvent A, wherein the ultrasonic power is 100-120W, the temperature is 50 ℃, the ultrasonic time is 45-50min, and filtering after the ultrasonic treatment is finished to obtain primary filtrate and primary residues;

b2, performing ultrasonic-assisted secondary extraction on the primary residue by using a double water phase solvent B, wherein the ultrasonic power is 100-120W, the temperature is 50 ℃, the ultrasonic time is 45-50min, and filtering after the ultrasonic treatment is finished to obtain secondary filtrate;

and B3, combining the primary filtrate and the secondary filtrate, concentrating, and vacuum drying to obtain the qu-zhi extract.

Further, the aqueous two-phase solvent A is an aqueous solution containing 19% of potassium carbonate and 27% of ethanol by mass fraction; the aqueous two-phase solvent B is an aqueous solution containing 15% of potassium carbonate and 32% of ethanol by mass.

Further, the preparation process of the krill oil comprises the following steps:

c1, drying and crushing euphausia superba, adding water according to a mass ratio of 1:4, regulating the temperature to 60 ℃, keeping for 10min, regulating the pH value to 8.5, adding 3000U/g protein alkaline protease with a material ratio of 0.01%, keeping away from light, stirring and carrying out enzymolysis for 2h, filtering by a 100-mesh filter screen, and collecting filtrate;

c2, regulating the pH value of the filtrate to 4.5, standing for 30min, centrifuging at 8000r/min to obtain pasty precipitate, and performing freeze drying treatment to obtain lipoprotein;

and C3, taking out lipoprotein, extracting krill oil with ethanol as an extraction solvent for 30min for 3 times, centrifuging to collect filtrate after extraction is finished, and drying in vacuum to obtain the krill oil.

Further, the feed liquid ratio of the extraction process in step C3 is 1g:9mL.

In a second aspect, the present invention provides a method for preparing a hypolipidemic composition comprising natural lovastatin, comprising the steps of:

s1, taking 10 parts of monascus lovastatin extract, 40 parts of qu bitter orange extract and 60 parts of krill oil, mixing and uniformly stirring to obtain an oily composition, preparing the oily composition into mother liquor by using ultrapure water, and reserving at 4 ℃;

s2, adding sodium ascorbate with the mass ratio of 2% into the mother liquor, wherein the mass ratio is 1:4, uniformly stirring to obtain emulsion, shearing and emulsifying the emulsion, and vacuum spray drying to obtain the lipid-lowering composition.

In a third aspect, the invention provides an application of a hypolipidemic composition containing natural lovastatin in hypolipidemic gel candy and hypolipidemic solid beverage:

the preparation method of the blood lipid-lowering gel candy comprises the following steps:

d1, preparation of gel candy contents: taking the monascus lovastatin extract and the qu bitter orange extract, fully mixing the monascus lovastatin extract and the qu bitter orange extract with krill oil, and sieving the mixture through a 80-mesh sieve after uniform mixing to obtain content feed liquid;

d2, glue solution preparation: mixing glycerol, sorbitol solution and purified water in a mixing device, heating to 60deg.C, adding gelatin, stirring, vacuumizing, filtering with 100 mesh sieve, standing, and maintaining temperature at 55-65deg.C for 1-4 hr to obtain gelatin solution;

and D3, pelleting: pressing the content liquid and the prepared glue solution into gel candy, wherein the temperature is 18-26 ℃ and the relative humidity is less than or equal to 50%, so as to obtain the gel candy;

d4, drying: and (3) drying the gel candy for 10-35 hours at 15-30 ℃ with the relative humidity less than 35% to obtain the dried gel candy.

The preparation of the lipid-lowering solid beverage comprises the following steps:

e1, taking an monascus lovastatin extract, a qu bitter orange extract, fully mixing with krill oil, and sieving with a 80-mesh sieve after uniformly mixing to obtain a lipid-lowering composition feed liquid;

e2, sequentially adding modified starch, chitosan, trehalose, sucrose, succinic acid monoglyceride and calcium ascorbate into water, stirring while adding to uniformly mix, and keeping the temperature of the solution at 50-95 ℃ to prepare an aqueous solution;

e3, mixing the lipid-lowering composition feed liquid with the aqueous solution, shearing for 10min at the rotating speed of 100000r/min, and repeatedly homogenizing for three times under the condition of 45Mpa to obtain the microemulsion;

and E4, reducing the temperature of the microemulsion to 1 ℃, then placing the microemulsion in a vacuum freeze-drying oven with the temperature of minus 40 ℃ and the pressure of 12Mpa, finally reducing the pressure to 1Mpa, reducing the temperature to minus 65 ℃, keeping the temperature for 3-5 hours, taking out and drying the obtained solid, and preparing the lipid-lowering solid beverage by powdering and sieving the obtained solid.

The invention has the beneficial effects that:

the invention adopts ethanol to extract natural monascus lovastatin in the functional red rice, the extraction rate reaches 75 percent, almost all natural monascus lovastatin in the functional red rice is reserved, and the oil-soluble functional red rice extract is obtained after the enzymatic hydrolysis of soybean lecithin and emulsification.

The invention adopts an ultrasonic-assisted double-water-phase system to extract flavonoid active ingredients in the qu fructus aurantii, adopts potassium carbonate and ethanol water solutions with different proportions to extract in two steps, and utilizes the selective characteristic of the double-water phase to perform targeted extraction on flavonoid substances in the components, thereby having high extraction efficiency and less impurities.

According to the preparation method, the krill oil is extracted in a biological enzymolysis mode, lipoprotein rich in the krill oil is obtained through freeze drying, the krill oil is extracted by taking ethanol as an extraction solvent, and the solvent is removed by evaporation to obtain the antarctic krill oil rich in phospholipids and astaxanthin.

The functional red yeast rice extract and krill oil can be prepared into the following functional food: solid beverages, liquid beverages, pressed candies, gel candies, and the like.

According to the invention, a hyperglycemic and hyperlipidemic zebra fish model is induced and suggested by using the hyperglycohyperlipidemic feed, and the cholesterol and triglyceride reducing effects of the hypolipidemic composition are analyzed; the results show that the composition has remarkable effects of reducing triglyceride and cholesterol in zebra fish, and has no larger difference compared with lovastatin which is a positive drug.

The invention adopts the high-sugar and high-fat feed to induce and establish a hyperlipidemia mouse model, analyzes the influence of the lipid-lowering composition on the weight, liver index and serum related index of the high-sugar and high-fat mouse, and results show that the lipid-lowering composition can obviously reduce the weight, triglyceride content, total cholesterol content, low-density lipoprotein and glutamic-pyruvic transaminase activity of the high-sugar and high-fat mouse and obviously increase the high-density lipoprotein and brown adipose tissue coefficient. Therefore, the composition plays a positive role in relieving obesity, reducing blood lipid and protecting liver.

The invention provides application of a blood lipid reducing composition in weight reduction, blood lipid reduction and liver protection, and provides a new resource for development of related products in the fields of biological medicines and health care products.

Drawings

The invention is further described below with reference to the accompanying drawings.

FIG. 1 is a dissected microscopic image of zebra fish in the triglyceride lowering efficacy evaluation of comparative example 1;

FIG. 2 is a table showing the effect of the hypolipidemic compound of comparative example 2 on the body weight and associated index of obese mice;

FIG. 3 is a table showing the effect of the lipid-lowering composition of comparative example 2 on serum IL-6 and TNF- α levels in hyperlipidemic mice.

Detailed Description

The technical solutions of the embodiments of the present invention will be clearly and completely described below in conjunction with the embodiments of the present invention, and it is apparent that the described embodiments are only some embodiments of the present invention, not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.

Example 1

Preparation of the monascus lovastatin extract:

a1, taking 5kg of functional red rice flour, crushing the functional red rice flour, sieving the crushed functional red rice flour with a 40-mesh sieve to obtain the functional red rice flour, and stirring and extracting the functional red rice flour by using 75% ethanol, wherein the mass ratio of the functional red rice flour to the ethanol is 7:1, extracting at 30 ℃ for 2 hours to obtain an extract after the extraction is completed, centrifugally separating the extract at 4000rpm/min, collecting supernatant, and repeating the extraction step twice;

a2, combining the two extracts, performing reduced pressure distillation at 35 ℃ and 0.06mpa vacuum degree, recovering ethanol solution, concentrating the ethanol solution, filtering at 20 ℃ and normal pressure to obtain red yeast extract, and performing vacuum reduced pressure drying at 60 ℃ to obtain extract;

and A3, placing the extract in an emulsifying kettle, adding 30% of enzymolysis soybean phospholipid (emulsifying agent) by weight of the extract, heating to 60 ℃, and emulsifying and stirring for 30min under the condition of 120r/min to obtain the oil-soluble monascus lovastatin extract.

Example 2

Preparation of the monascus lovastatin extract:

a1, taking 5kg of functional red rice flour, crushing the functional red rice flour, sieving the crushed functional red rice flour with a 40-mesh sieve to obtain the functional red rice flour, and stirring and extracting the functional red rice flour by using 75% ethanol, wherein the mass ratio of the functional red rice flour to the ethanol is 7:1, extracting at the temperature of 32 ℃ for 2 hours, obtaining an extract after the extraction is completed, centrifugally separating the extract at 4000rpm/min, collecting supernatant, and repeating the extraction step twice;

a2, combining the two extracts, performing reduced pressure distillation at 38 ℃ and 0.07mpa vacuum degree, recovering ethanol solution, concentrating the ethanol solution, filtering at 20 ℃ and normal pressure to obtain red yeast extract, and performing vacuum reduced pressure drying at 60 ℃ to obtain an extract;

Example 3

Preparation of the monascus lovastatin extract:

a1, taking 5kg of functional red rice flour, crushing the functional red rice flour, sieving the crushed functional red rice flour with a 40-mesh sieve to obtain the functional red rice flour, and stirring and extracting the functional red rice flour by using 75% ethanol, wherein the mass ratio of the functional red rice flour to the ethanol is 7:1, extracting at 35 ℃ for 2 hours to obtain an extract after the extraction is completed, centrifugally separating the extract at 4000rpm/min, collecting supernatant, and repeating the extraction step twice;

a2, combining the two extracts, performing reduced pressure distillation at 40 ℃ and 0.08mpa vacuum degree, recovering ethanol solution, concentrating the ethanol solution, filtering at 20 ℃ and normal pressure to obtain red yeast extract, and performing vacuum reduced pressure drying at 60 ℃ to obtain extract;

Example 4

Preparation of fructus Aurantii extract:

b1, taking 5kg of bitter orange, crushing, sieving with a 40-mesh sieve for later use, preparing a double-aqueous phase solvent containing 19% of potassium carbonate and 27% of ethanol by mass, performing ultrasonic auxiliary extraction on the bitter orange powder by using the double-aqueous phase solvent, performing ultrasonic power of 100W, the temperature of 50 ℃ and the ultrasonic time of 45min, and filtering after the ultrasonic treatment is finished to obtain primary filtrate and primary residues;

b2, performing ultrasonic-assisted secondary extraction on the primary residues after the primary extraction by using a water-in-water phase solution of 15% of potassium carbonate and 32% of ethanol, wherein the ultrasonic power is 100W, the temperature is 50 ℃, the ultrasonic time is 45min, and filtering is performed after the ultrasonic treatment is finished to obtain secondary filtrate;

Example 5

Preparation of fructus Aurantii extract:

b1, taking 5kg of bitter orange, crushing, sieving with a 40-mesh sieve for later use, preparing a double-aqueous phase solvent containing 19% of potassium carbonate and 27% of ethanol by mass, performing ultrasonic auxiliary extraction on the bitter orange powder by using the double-aqueous phase solvent, performing ultrasonic power 110W, temperature 50 ℃ and ultrasonic time 50min, and filtering after ultrasonic treatment is finished to obtain primary filtrate and primary residues;

b2, performing ultrasonic-assisted secondary extraction on the primary residues after the primary extraction by using a water-in-water phase solution of 15% of potassium carbonate and 32% of ethanol, wherein the ultrasonic power is 110W, the temperature is 50 ℃, the ultrasonic time is 50min, and filtering is performed after the ultrasonic treatment is finished to obtain secondary filtrate;

Example 6

Preparation of fructus Aurantii extract:

b1, taking 5kg of bitter orange, crushing, sieving with a 40-mesh sieve for later use, preparing a double-aqueous phase solvent containing 19% of potassium carbonate and 27% of ethanol by mass, performing ultrasonic auxiliary extraction on the bitter orange powder by using the double-aqueous phase solvent, performing ultrasonic power of 120W, the temperature of 50 ℃ and the ultrasonic time of 50min, and filtering after the ultrasonic treatment is finished to obtain primary filtrate and primary residues;

b2, performing ultrasonic-assisted secondary extraction on the primary residues after the primary extraction by using a water-in-water phase solution of 15% of potassium carbonate and 32% of ethanol, wherein the ultrasonic power is 120W, the temperature is 50 ℃, the ultrasonic time is 50min, and filtering is performed after the ultrasonic treatment is finished to obtain secondary filtrate;

Example 7

Preparation of krill oil:

heating 10kg of antarctic krill, drying, crushing, adding water according to a mass ratio of 1:4, adjusting the temperature to 60 ℃, keeping for 10min, adjusting the pH value to 8.5, adding 3000U/g protein alkaline protease with a material ratio of 0.01%, keeping away from light, stirring for enzymolysis for 2h, filtering with a 100-mesh filter screen, and collecting filtrate;

and C3, taking out lipoprotein, extracting krill oil by using ethanol as an extraction solvent for 3 times, wherein the ratio of the extracted feed liquid to the extracted feed liquid is 1g:9mL, the time is 30min, after the extraction is finished, filter residues are removed by centrifugation, and the filtrate is evaporated in vacuum to recover the solvent, so that krill oil is obtained.

Example 8

A preparation method of a blood lipid-lowering composition containing natural lovastatin:

the hypolipidemic composition containing natural lovastatin comprises the following raw materials in parts by weight:

10 parts of the monascus lovastatin extract prepared in example 1;

40 parts of the qu bitter orange extract prepared in the example 4;

60 parts of krill oil prepared in example 7;

a method for preparing a hypolipidemic composition containing natural lovastatin, comprising the steps of:

s1, mixing 10 parts of the monascus lovastatin extract, 40 parts of the qu bitter orange extract and 60 parts of the krill oil uniformly, and stirring to obtain an oily composition, wherein the oily composition is prepared into mother liquor by using ultrapure water, and the temperature is 4 ℃ for later use;

Example 9

10 parts of the monascus lovastatin extract prepared in example 2;

40 parts of the qu bitter orange extract prepared in the example 5;

60 parts of krill oil prepared in example 7;

Example 10

10 parts of the monascus lovastatin extract prepared in example 3;

40 parts of the qu bitter orange extract prepared in the example 6;

60 parts of krill oil prepared in example 7;

Comparative example 1

Evaluation of efficacy of hypolipidemic compositions containing natural lovastatin:

(1) Experimental materials and experimental methods:

a. sample preparation information:

taking the oily composition in the step S1 in the example 9, preparing 200mg/mL mother liquor by using ultrapure water, and preserving at 4 ℃ for later use;

positive control: lovastatin, white powder, lot number 55FIB-JP, dried in the shade and stored. Preparing mother liquor of 8.00mg/mL with DMSO, and sub-packaging at-20deg.C.

b. Experimental animals:

zebra fish are all raised in water quality of fish culture water at 28℃: 200mg of instant sea salt is added into each 1L of reverse osmosis water, and the conductivity is 450-550 mu S/cm; the pH is 6.5-8.5; hardness of 50-100mg/L (CaCO) ₃ Content), provided by the cyclophilia organism, the experimental animal use license number is: SYXK (Zhe) 2022-0004, the feeding management meets the requirements of International AAALAC authentication (authentication number: 001458).

The melanin allele mutant semitransparent Albino strain zebra fish is carried out in a natural pairing mating propagation mode. Zebra fish aged 5 days after fertilization (5 dpf) were used for maximum detection concentration (MTC) determination of blood lipid lowering efficacy and triglyceride lowering efficacy evaluation of samples.

Wild type AB strain zebra fish is bred in a natural pairing mating breeding mode. Zebra fish of age 5dpf (days post fertilization) were used for sample cholesterol lowering efficacy evaluation.

c. Maximum Tolerance Concentration (MTC) assay

The 5dpf zebra fish were randomly selected in beakers, and 30 zebra fish were treated per cup (experimental group). The mother liquor was given in water-soluble form, and a normal control group and a model control group were simultaneously set, with a capacity of 25mL per cup. Except for the normal control group, all the other experimental groups are water-soluble and are given with high-sugar and high-fat feed, and a zebra fish high-sugar and high-fat model is built. After 48h of treatment at 28 ℃, the MTC of the lipid-lowering composition was determined for model zebra fish.

d. Evaluation of triglyceride-lowering efficacy

The 5dpf zebra fish were randomly selected in beakers, and 30 zebra fish were treated per cup (experimental group). The sample (200 mg/mL mother liquor/lovastatin) was given in water, the positive control lovastatin at a concentration of 0.080. Mu.g/mL, and the normal control group and the model control group were simultaneously set at a capacity of 25mL per cup. Except for the normal control group, all the other experimental groups are water-soluble and are given with high-sugar and high-fat feed, and a zebra fish high-sugar and high-fat model is built. After 48h of treatment at 28 ℃, oil red O was given for bulk fat staining. After the dyeing is finished, 10 zebra fish are randomly selected from each experimental group, photographed under an dissecting microscope, analyzed and data are collected by Image-ProPlus advanced Image processing software, the blood vessel dyeing intensity of the zebra fish tail is analyzed, and the triglyceride reducing efficacy of the sample is evaluated by the statistical analysis result of the index. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant.

e. Evaluation of cholesterol lowering efficacy

The 5dpf wild type AB strain zebra fish were randomly selected in beakers, and 30 zebra fish were treated per cup (experimental group). The sample (200 mg/mL mother liquor/lovastatin) was given in water, the positive control lovastatin at a concentration of 0.080. Mu.g/mL, and the normal control group and the model control group were simultaneously set at a capacity of 25mL per cup. Except for the normal control group, all the other experimental groups are water-soluble and are given with high-sugar and high-fat feed, and a zebra fish high-sugar and high-fat model is built. 3 biological replicates were run in parallel. After 48 hours of treatment at 28 ℃, zebra fish samples are collected according to the specification of a total cholesterol detection kit, the cholesterol content in the zebra fish is detected by a multifunctional enzyme-labeled instrument, and the cholesterol reducing effect of the samples is evaluated according to the statistical analysis result of the index. Statistical treatment results are expressed in mean+ -SE. Statistical analysis was performed with SPSS26.0 software, p <0.05 indicated that the differences were statistically significant.

(2) Experimental results

a. Maximum Tolerated Concentration (MTC), see table 1 below:

table 1. Experimental results of experimental results (n=30) were found for the hypolipidemic efficacy concentration of the samples

As can be seen from table 1: under the experimental condition, the mother liquor has the blood lipid reducing effect MTC of 125 mug/mL.

b. Triglyceride lowering efficacy evaluation, see table 2 below and fig. 1:

table 2. Results of experiments for evaluating the efficacy of reducing triglyceride of samples (n=10)

Group of	Concentration (μg/mL)	Tail vascular staining intensity (pixel ± SE)
			Normal control group	-	557±49.3***
Model control group	-	13897±730
			Lovastatin	0.080	3079±307***
Mother liquor	125	3856±327***

P <0.001, compared to model control, has statistical significance.

As can be seen from table 2 and fig. 1, the composition mother liquor prepared by the invention has remarkable triglyceride reducing effect in zebra fish, and has no large difference compared with lovastatin which is a positive drug.

c. Cholesterol lowering efficacy evaluation, see table 3 below:

table 3. Results of experiments for evaluating cholesterol lowering efficacy of samples (n=3)

Group of	Concentration (μg/μl)	Cholesterol (mmol/g, mean.+ -. SE)
			Normal control group	-	0.042±0.003***
Model control group	-	0.127±0.009
			Lovastatin	0.080	0.081±0.006*
Mother liquor	125	0.060±0.009*

P <0.05, < p <0.001, has statistical significance compared to model control.

As can be seen from table 3, the composition mother liquor prepared by the invention has remarkable cholesterol reducing effect in zebra fish, and has no larger difference compared with lovastatin which is a positive drug.

Comparative example 2

Influence of hypolipidemic composition on body weight adipose tissue and serum related index of high-sugar high-fat mice:

(1) Experimental animals:

SPF-class male C57BL/6J mice, 7 weeks old, weighing 19-21g, and raising at 21+ -2deg.C and humidity 55+ -10% with 12h alternation. After 1 week of acclimation, the mice were randomly divided into 5 treatments (control, high fat, lovastatin, monascus, krill oil, bitter orange, and lipid-lowering composition) 10 per group and three replicates.

(2) The experimental method comprises the following steps:

control mice were fed regular diet and high fat group and sample group mice were fed diet high in fat with 60%. After 8 weeks of feeding, the control group and the high fat group mice were perfused with 0.8% physiological saline (100. Mu.L/d), and the red yeast group, krill oil group, qu-zhi group, lipid-lowering composition (oily composition in step S1 in example 9) groups of mice were perfused with the red yeast extract, qu-zhi extract, krill oil, and lipid-lowering composition at a dose of 125mg/kg/d, respectively, and the mice were fed and drunk freely during the experiment, and the body weight and feeding amount of the mice were recorded weekly.

Fasted for 24 hours in 14-week stomach-filled mice, weighing, measuring body length, and calculating weight gain, weight gain rate and Lee's index; collecting mouse blood, and detecting TC, TG, LDL-C and HDL-C levels in mouse serum; mouse livers were collected and assayed for TNF- α, IL-6, T-AOC, T-SOD and MDA levels according to kit instructions.

(3) Experimental results:

a. the effect of lipid-lowering compositions on body weight and related index of obese mice is shown in figure 2:

as shown in fig. 2, after 14 weeks of the intervention of the monascus krill oil, the weight, weight gain rate and Lee's index of the mice in the high-fat group were significantly increased compared with those in the control group, while the weight, weight gain rate and Lee's index of the mice in the lipid-lowering composition group were not significantly different, and the weight gain of the mice in the lipid-lowering composition group and the weight gain of the mice in the high-fat group were extremely significantly different, indicating that the lipid-lowering composition was capable of alleviating the weight gain of the mice induced by the high-fat diet, and the weight-reducing effect was superior to that of the single formulation group of the monascus, the bitter orange and the krill oil.

b. The effect of the hypolipidemic composition compound on the blood lipid of obese mice is shown in table 4 below:

TABLE 4 Effect of lipid-lowering compositions on blood lipid levels in mice

P <0.05, < p <0.001, has statistical significance compared to model control.

As can be seen from table 4: the serum TC, TG, LDL-C content of the mice in the model group is significantly increased and the HDL-C content is significantly decreased (P < 0.05) compared with the normal control group. Compared with the model group, the contents of TC and TG in the monascus, the qu bitter orange, the krill oil and the lipid-lowering composition group are obviously reduced, the LDL-C content of the mice in each administration group is obviously reduced, and the HDL-C content is obviously increased (P < 0.05).

c. The effect of lipid-lowering compositions on mouse serum IL-6 and TNF- α levels is shown in FIG. 3:

IL-6 and TNF- α play an important role in the process of inflammatory injury. FIG. 3 is a graph showing the effect of lipid lowering compositions on serum IL-6 and TNF- α levels in hyperlipidemic mice. Serum IL-6 and TNF- α levels were significantly higher in the mice of the high-fat model group than in the normal group (P < 0.05), suggesting that the high-fat diet resulted in inflammatory injury to the mice. Compared with a high-fat model group, the serum IL-6 level of mice in the monascus, the qu-bitter orange, the krill oil and the lipid-lowering composition group is respectively reduced by 13.29%, 14.36%, 21.02% and 27.46%, and the TNF-alpha level is respectively reduced by 15.12%, 16.48%, 30.40% and 43.52%, which are all obviously lower than that in the model group (P < 0.05), thus showing that the effect of the lipid-lowering composition compound on relieving inflammatory injury of the mice with hyperlipidemia is superior to that of the single formula.

d. The effect of lipid-lowering composition compound on the antioxidant capacity of the liver of mice is shown in table 5 below:

TABLE 5 Effect of lipid-lowering compositions on serum SOD, T-AOC, MDA in obese rats

Group of	SOD/(U/mL)	T-AOC/(unit/mL)	MDA/(nmol/mL)
				Normal group	631.78±143.68***	2.94±0.51***	32.04±9.60**
Model group	260.32±120.31	1.02±1.46	49.09±10.76
				Lovastatin	406.34±78.89**	1.92±0.45	40.45±13.11
Red rice group	410.84±113.33*	1.89±1.5	45.07±10.85
				Krill oil group	450.87±110.25**	2.18±0.98	33.85±11.04*
Fructus Aurantii group	460.84±103.43*	2.06±2.3	40.38±8.99
				Lipid-lowering composition group	589.74±69.26***	2.65±0.97	35.76±9.95*

P <0.05, P <0.01, P <0.0001, has statistical significance compared to model control.

As can be seen from table 5: T-AOC reflects the total antioxidant capacity of the organism, and T-SOD plays an important role in the oxidation and antioxidant balance of the organism. The effect of the lipid-lowering composition on the activity of T-AOC and T-SOD in the liver of mice with hyperlipidemia is shown in Table 5, and the activity of T-AOC and T-SOD in the liver of mice with hyperlipidemia model group is reduced by 34.6% and 41.2% respectively compared with that in normal group, and both are significantly lower than that in normal group (P < 0.05), which suggests that the liver of mice with hyperlipidemia caused by high lipid diet is in oxidative stress state. In the red yeast rice, the bitter orange and the krill oil group, the activity of the T-AOC and the T-SOD of the liver of the mice is obviously higher than that of a high-fat model group (P < 0.05), and the activity of the T-AOC and the T-SOD of the mice in the lipid-lowering composition group is recovered to the normal level (P > 0.05), which indicates that the lipid-lowering composition can play a role in protecting the mice with hyperlipidemia by improving the antioxidant capacity of organisms.

Elevated MDA levels are considered an important marker of lipid peroxidation in the body, and a 28% decrease in liver MDA levels in mice in the lipid-lowering composition group compared to the high-lipid model group is significantly lower than in the model group (P < 0.05), suggesting that the composition can alleviate lipid oxidative damage in liver tissue induced by high-lipid diet.

Example 11

Preparation of gel candy for reducing blood fat:

d1, preparation of gel candy contents: taking 1kg of the monascus lovastatin extract prepared in the example 1 and 2kg of the qu bitter orange extract prepared in the example 4, fully mixing with 8kg of the krill oil prepared in the example 7, and sieving with a 80-mesh sieve to obtain a content feed liquid;

d2, glue solution preparation: mixing glycerol, sorbitol solution and purified water in a mixing device, heating to 60deg.C, adding gelatin, stirring, vacuumizing, filtering with 100 mesh sieve, standing, and maintaining temperature at 55deg.C for 1 hr to obtain gelatin solution;

and D3, pelleting: pressing the content liquid and the prepared glue solution into gel candy at 18 ℃ with the relative humidity less than or equal to 50%, so as to obtain 750 mg/grain gel candy;

d4, drying: and (3) drying the gel candy for 10 hours, wherein the drying temperature is 15 ℃, and the relative humidity is less than 35%, so that the dried gel candy is obtained.

Example 12

Preparation of gel candy for reducing blood fat:

d1, preparation of gel candy contents: taking 1kg of the monascus lovastatin extract prepared in the example 2 and 2kg of the qu bitter orange extract prepared in the example 5, fully mixing with 8kg of the krill oil prepared in the example 7, and sieving with a 80-mesh sieve to obtain a content feed liquid;

d2, glue solution preparation: mixing glycerol, sorbitol solution and purified water in a mixing device, heating to 70deg.C, adding gelatin, stirring, vacuumizing, filtering with 100 mesh sieve, standing, and maintaining at 60deg.C for 2 hr to obtain gelatin solution;

and D3, pelleting: pressing the content liquid and the prepared glue solution into gel candy at 24 ℃ with the relative humidity less than or equal to 50%, so as to obtain 750 mg/grain gel candy;

d4, drying: and (3) drying the gel candy for 20 hours, wherein the drying temperature is 20 ℃, and the relative humidity is less than 35 percent, so that the dried gel candy is obtained.

Example 13

Preparation of gel candy for reducing blood fat:

d1, preparation of gel candy contents: taking 1kg of the monascus lovastatin extract prepared in the example 3 and 2kg of the qu bitter orange extract prepared in the example 6, fully mixing with 8kg of the krill oil prepared in the example 7, and sieving with a 80-mesh sieve to obtain a content feed liquid;

d2, glue solution preparation: mixing glycerol, sorbitol solution and purified water in a mixing device, heating to 80deg.C, adding gelatin, stirring, vacuumizing, filtering with 100 mesh sieve, standing, and maintaining at 65deg.C for 4 hr to obtain gelatin solution;

and D3, pelleting: pressing the content liquid and the prepared glue solution into gel candy at 26 ℃ with the relative humidity less than or equal to 50%, so as to obtain 750 mg/grain gel candy;

d4, drying: and (3) drying the gel candy for 35 hours, wherein the drying temperature is 30 ℃, and the relative humidity is less than 35 percent, so that the dried gel candy is obtained.

Example 14

Preparation of lipid-lowering solid beverage:

e1, taking 5kg of the monascus lovastatin extract prepared in the example 1, 2kg of the qu bitter orange extract prepared in the example 4, fully mixing with 50kg of the krill oil prepared in the example 7, and sieving with a 80-mesh sieve to obtain lipid-lowering composition feed liquid;

2, sequentially adding 5kg of modified starch, 9kg of chitosan, 0.05kg of trehalose, 0.05kg of sucrose, 0.05kg of succinic acid monoglyceride and 0.02kg of calcium ascorbate into 26kg of water, stirring while adding to uniformly mix, and keeping the solution temperature at 50 ℃ to prepare an aqueous solution;

and E4, reducing the temperature of the microemulsion to 1 ℃, then placing the microemulsion in a vacuum freeze-drying oven with the pressure of-40 ℃ and the pressure of 12Mpa, finally reducing the pressure to 1Mpa, reducing the temperature to-65 ℃, keeping the temperature for 3 hours, taking out and drying the obtained solid, and preparing the lipid-lowering solid beverage by powdering and sieving the obtained solid.

Example 15

Preparation of lipid-lowering solid beverage:

e1, taking 5kg of the monascus lovastatin extract prepared in the example 2, 2kg of the qu bitter orange extract prepared in the example 5, fully mixing with 50kg of the krill oil prepared in the example 7, and sieving with a 80-mesh sieve to obtain lipid-lowering composition feed liquid;

2, sequentially adding 5kg of modified starch, 9kg of chitosan, 0.05kg of trehalose, 0.05kg of sucrose, 0.05kg of succinic acid monoglyceride and 0.02kg of calcium ascorbate into 26kg of water, stirring while adding to uniformly mix, and keeping the solution temperature at 80 ℃ to prepare an aqueous solution;

and E4, reducing the temperature of the microemulsion to 1 ℃, then placing the microemulsion in a vacuum freeze-drying oven with the pressure of-40 ℃ and the pressure of 12Mpa, finally reducing the pressure to 1Mpa, reducing the temperature to-65 ℃, keeping the temperature for 4 hours, taking out and drying the obtained solid, and preparing the lipid-lowering solid beverage by powdering and sieving the obtained solid.

Example 16

Preparation of lipid-lowering solid beverage:

e1, taking 5kg of the monascus lovastatin extract prepared in the example 3, 2kg of the qu bitter orange extract prepared in the example 6, fully mixing with 50kg of the krill oil prepared in the example 7, and sieving with a 80-mesh sieve to obtain lipid-lowering composition feed liquid;

2, sequentially adding 5kg of modified starch, 9kg of chitosan, 0.05kg of trehalose, 0.05kg of sucrose, 0.05kg of succinic acid monoglyceride and 0.02kg of calcium ascorbate into 26kg of water, stirring while adding to uniformly mix, and keeping the solution temperature at 95 ℃ to prepare an aqueous solution;

and E4, reducing the temperature of the microemulsion to 1 ℃, then placing the microemulsion in a vacuum freeze-drying oven with the pressure of-40 ℃ and the pressure of 12Mpa, finally reducing the pressure to 1Mpa, reducing the temperature to-65 ℃, keeping the temperature for 5 hours, taking out and drying the obtained solid, and preparing the lipid-lowering solid beverage by powdering and sieving the obtained solid.

It should be noted that in this document, terms such as "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.

Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made therein without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.

Claims

1. The hypolipidemic composition containing natural lovastatin is characterized by comprising the following raw materials in parts by weight:

10 parts of monascus lovastatin extract;

40 parts of fructus aurantii extract;

60 parts of krill oil.

2. The hypolipidemic composition comprising natural lovastatin according to claim 1, characterized in that the process for the preparation of the monascus lovastatin extract comprises the following steps:

3. The hypolipidemic composition containing natural lovastatin according to claim 2, wherein the mass ratio of the functional red rice flour to ethanol in step A1 is 7:1.

4. the hypolipidemic composition of claim 2, wherein the amount of enzymatically hydrolyzed soy phospholipid in step A3 is 30% of the extract mass.

5. The hypolipidemic composition comprising natural lovastatin according to claim 1, wherein the preparation process of the qu-fructus aurantii extract comprises the following steps:

6. The hypolipidemic composition containing natural lovastatin as claimed in claim 5, wherein the aqueous two-phase solvent a is an aqueous solution containing 19% by mass of potassium carbonate and 27% by mass of ethanol; the aqueous two-phase solvent B is an aqueous solution containing 15% of potassium carbonate and 32% of ethanol by mass.

7. The hypolipidemic composition comprising natural lovastatin according to claim 1, wherein the krill oil is prepared by a process comprising the steps of:

and C3, taking out lipoprotein, extracting krill oil by using ethanol as an extraction solvent, wherein the extraction times are 3 times, and the feed-liquid ratio in the extraction process is 1g:9mL, 30min, centrifuging to collect filtrate after extraction, and vacuum drying to obtain krill oil.

8. Use of a hypolipidemic composition comprising natural lovastatin, characterized in that the hypolipidemic composition according to any one of claims 1 to 7 is used in hypolipidemic gel candies and hypolipidemic solid beverages.

9. The use of a hypolipidemic composition comprising natural lovastatin according to claim 8, characterized in that the hypolipidemic gel candy is prepared by:

10. The use of a lipid-lowering composition containing natural lovastatin as claimed in claim 8, wherein the lipid-lowering solid beverage is prepared by: